Structural Heart Imaging Market Size, Share, and Industry Analysis By Modality (Computed Tomography (CT), Angiogram, Magnetic Resonance Imaging (MRI), Echocardiogram, & Others), By Procedure (Transcatheter Aortic Valve Implantation (TAVI), Mitral Replacement and Repair (TMVR and TMVr), Pulmonary Valve Implantation, Tricuspid Replacement and Repair (TTVR and TTVr), Left Atrial Appendage Occlusion, & Others), By Application (Diagnosis and Interventional Cardiology), By End User (Hospitals & ASCs, Specialty Clinics, & Diagnostic Imaging Centers) and Regional Forecast, 2026-2034

The global structural heart imaging market size was valued at USD 9.99 billion in 2025. The market is projected to grow from USD 10.6 billion in 2026 to USD 16.94 billion by 2034, exhibiting a CAGR of 6.04% during the forecast period.

The global structural heart imaging market is anticipated to depict significant expansion owing to a rise in the prevalence of cardiovascular disorders, including congenital heart defects and valve disorders. Structural heart imaging assists healthcare professionals in assessing the heart function and structure of a patient. It involves the use of imaging techniques such as cardiac CT scans, echocardiography, and fluoroscopy for planning cardiac surgeries.

• According to PubMed Central (PMC), more than 1 in 8 individuals in the age group of 75 and above have severe or moderate aortic stenosis.

Structural Heart Imaging Market Driver

Rising Demand for Minimally Invasive Procedures to Foster the Demand for Advanced Imaging Technologies

Accurate imaging technologies are witnessing a high demand amid an increase in minimally invasive procedures for the treatment of various heart conditions. According to PMC, valve repair has been proven to enhance outcomes and decrease mortality by 70% in degenerative mitral regurgitation patients.

Recent years have recorded substantial innovations in imaging procedures. CT, cardiac MRI, and 3D echocardiography are some of the technologies that have been claimed to offer non-invasive and accurate diagnosis. The technology adoption is rising with soaring awareness regarding heart health and a heightened demand for early disease diagnosis.

Structural Heart Imaging Market Restraint

Shortage of Skilled Professionals and High Equipment Cost May Affect Market Expansion

The high costs associated with advanced imaging procedures and equipment may limit their adoption particularly in developing countries. A delay in regulatory approvals for new technologies due to complex and lengthy processes can also slow up product launches. Another factor that may impede the market is the shortage of skilled professionals for operating the equipment.

Structural Heart Imaging Market Opportunity

Mounting Launch of AI/ML-Integrated Solutions to Offer New Growth Avenues

The integration of advanced technologies such as machine learning (ML) and artificial intelligence (AI) into imaging solutions for accurate and faster diagnosis is slated to create new opportunities for industry players. The soaring cardiovascular disease burden in China, India, and Latin America and substantial investments toward the development of healthcare infrastructure are also poised to lay the groundwork for new avenues in the future.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of Cardiovascular Diseases, By Key Countries
• Diagnostic Statistics for Cardiac Diseases across Major Countries
• Major Market Drivers, Trends, and Investment Opportunities
• Business Strategies Adopted by Key Players and Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Overview: Regulatory Scenario and Government Policies

Analysis by Modality

By modality, the structural heart imaging market is divided into computed tomography (CT), angiogram, magnetic resonance imaging (MRI), echocardiogram, and others.

The computed tomography (CT) segment is projected to lead the global market. CT scans are gaining traction as they are increasingly being preferred for assessing the heart structure and blood flow. The tests also help detect the risk of a heart attack which is a major factor bolstering the expansion of the segment. As per data by PMC, the standard pre-procedural imaging for left atrial appendage occlusion was transesophageal echocardiography; nonetheless, CT imaging is gaining popularity for the same in recent years.

The angiogram segment is anticipated to depict considerable expansion due to an increase in the incidences of cardiovascular diseases. The modality is considered as an effective and safe way of treating and diagnosing artery issues. The increasing advancements focused on improving the accuracy of angiograms is set to drive segment growth.

Analysis by Procedure

Based on procedure, the market is subdivided into transcatheter aortic valve implantation (TAVI), mitral replacement and repair (TMVR and TMVr), pulmonary valve implantation (PPVI), tricuspid replacement and repair (TTVR and TTVr), left atrial appendage occlusion (LAAO), and others.

The demand for TAVI (transcatheter aortic valve implantation) is estimated to record significant growth due to surging advancements in minimally invasive procedures. These surgeries are set to depict a high adoption of advanced structural heart imaging technologies for enhancing their success rate and providing appropriate care to patients.

The mitral replacement and repair (TMVR and TMVr) segment is recording considerable growth owing to an increase in the prevalence of mitral valve disease. According to PMC, transcatheter mitral valve interventions are considered as alternative options for treating mitral regurgitation patients who are not suitable for open-heart surgery. This is a key factor influencing segment growth.

Analysis by Application

By application, the market is fragmented into diagnosis and interventional cardiology.

The diagnosis segment dominates the global market owing to an increase in the adoption of structural heart imaging technologies in diagnostic centers for assessing the risk of heart attacks. For instance, around 1 in 10 individuals in the age group of 75 and above have severe or moderate mitral regurgitation, cites PMC. The segment is expanding due to the increasing awareness of heart health and cardiac care.

A surge in the deployment of imaging technologies for guiding cardiac procedures is propelling the significant expansion of the interventional cardiology segment. For instance, two most used devices for LAAO (left atrial appendage occlusion) procedure are Amplatzer, offered by Abbott Vascular, and Watchman, provided by Boston Scientific Corporation.

Analysis by End User

Based on end user, the structural heart imaging market is divided into hospitals & ASCs, specialty clinics, diagnostic imaging centers, and others.

The hospitals & ASCs segment is anticipated to dominate the market over the coming years as these establishments depict a rising adoption of imaging technologies for supporting a range of interventional procedures. The technologies are helpful in influencing the success of these procedures considering their complexities. As per PMC, the past decades have recorded a dramatic rise in the number of transcatheter treatments for structural heart diseases.

A rise in the number of people opting for diagnostic services is driving the product adoption in diagnostic imaging centers. The segment is estimated to exhibit considerable growth in the future. The frequency of health checkups is surging with an increasing number of cardiovascular diseases and mounting health consciousness among people.

Regional Analysis

Based on region, the structural heart imaging market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America dominates the global market. The region shows an escalating prevalence of cardiovascular disorders. According to PMC, the number of individuals with moderate or severe tricuspid regurgitation is between 1 and 6. Furthermore, the region exhibits the deployment of cutting-edge technologies such as MRI and 3D echocardiography and high expenditure on healthcare services.

Europe records the presence of a robust healthcare infrastructure and holds the second-leading share in the global market. This is mainly due to a rise in government investments focused on the management of heart diseases. Furthermore, the region depicts the extensive availability of advanced imaging technologies and the need for better diagnostic solutions amid an aging population.

The Asia Pacific market is anticipated to register considerable expansion favored by the surging demand for advanced diagnostic tools and the escalating prevalence of cardiovascular diseases. India and China depict an escalating adoption of heart imaging technologies and increasing investments driven by the expansion of healthcare infrastructure and large patient populations.

Key Players Covered

The report includes the profiles of the following key players:

• Siemens Healthcare (Germany)
• Koninklijke Philips N.V. (Netherlands)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• Fujifilm Holdings Corporation (Japan)
• Shanghai United Imaging Healthcare Co., LTD (China)
• TERUMO CORPORATION (Japan)
• Boston Scientific Corporation (U.S.)
• GE HealthCare (U.S.)
• Circle Cardiovascular Imaging Inc. (Canada)
• Pie Medical Imaging B.V. (Netherlands)

Key Industry Developments

• In August 2024, Siemens Healthineers secured the clearance of the U.S. FDA (Food and Drug Administration) for Acuson Origin. The solution is a new cardiovascular ultrasound system equipped with AI (artificial intelligence) capabilities.
• In August 2023, Canon Medical launched the Alphenix Evolve edition, an angiography system for structural heart disease and PCI (percutaneous coronary intervention) procedures. The solution has been designed to improve imaging, enabling reduced radiation dose and time during complex and routine procedures.
• In November 2022, Fujifilm Healthcare Americas Corporation launched the Scenaria View Focus Edition CT (Computed Tomography) system. The solution has been equipped with Cardio StillShot, an advanced Cardiac Motion Correction feature.